(Q38221692)

31 August 2017

title

Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer (English)

1 reference

31 August 2017

1 reference

1 reference

1 reference

Meaghan L Khan

1

1 reference

31 August 2017

Thorvardur R Halfdanarson

series ordinal

2

1 reference

31 August 2017

Mitesh J Borad

series ordinal

3

1 reference

31 August 2017

language of work or name

English

0 references

publication date

1 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

10

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

1255-1275

1 reference

Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Vaccines for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Mucin-based targeted pancreatic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Reovirus: a targeted therapeutic--progress and potential

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Structure and biology of a carcinoma-associated mucin, MUC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Mucins in cancer: protection and control of the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Tumor-induced immunosuppression: a barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Cytosolic entry controls CD8+-T-cell potency during bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Dendritic cell cross-priming is essential for immune responses to Listeria monocytogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Immunotherapy updates in pancreatic cancer: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

The alpha-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Principles of adoptive T cell cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Mesothelin-targeted agents in clinical trials and in preclinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Viruses as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Modification of mammalian reoviruses for use as oncolytic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Reovirus as an oncolytic agent against experimental human malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Reovirus oncolysis of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Vector-mediated cancer gene therapy: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Cell-cycle targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Spatial and temporal control of gene therapy using ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.277

21 January 2018

Identifiers

DOI

10.2217/FON.13.277

1 reference

31 August 2017

1 reference